Table 4 Costs incremental health outcomes and cost-utility of pre-referral antimalarial treatments by healthcare provider
Scenario | Intervention | Costs for a cohort of 1000 children ($) | DALYs | DALYs averted | Incremental cost ($) | ICER ($ per DALY averted) |
|---|---|---|---|---|---|---|
Base model | No treatment | 0.89 | 20,122 | – | – | – |
CHW | 85,491 | 4587 | 15,535 | 85,490 | 5.50 | |
PHF | 88,961 | 7512 | 12,610 | 88,960 | 7.05 | |
THF | 123,711 | 2186 | 17,936 | 123,710 | 6.90 | |
Probabilistic sensitivity analysis | No treatment | 0.88 [0.88–0.88] | 19,529 [15,315, 24,737] | – | – | – |
CHW | 68,428 [43,362, 100,703] | 5413 [3091, 8430] | 13,276 [9534, 17,684] | 68,427 [43,361, 100,702] | 5.11 [3.01, 8.21] | |
PHF | 73,825 [47,531, 103,875] | 8328 [5030, 12,531] | 9993 [6180, 14,429] | 73,825 [47,530, 103,874] | 7.30 [5.30, 11.20] | |
THF | 114,903 [91,842, 145,168] | 3111 [1801, 5005] | 15,801 [11,990, 20,375] | 114,902 [91,841, 145,167] | 7.14 [5.10, 10.92] |